Ex-KuDOS team raise £6 million for new venture
This article was originally published in Scrip
A management team originating from AstraZeneca buy-out KuDOS Pharmaceuticals has raised £6 million of venture financing to launch a new company. The investor syndicate was led by Sofinnova Partners, and included Imperial Innovations and two corporate venture investors, GlaxoSmithKline’s SR One and the Roche Venture Fund.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.